A PHASE 1/2, OPEN LABEL, FIRST-IN-HUMAN, DOSE ESCALATION AND EXPANSION STUDY OF SAR445877 ADMINISTERED AS MONOTHERAPY IN ADULTS WITH ADVANCED SOLID TUMORS

1Martin Gutierrez*, 2Elena Garralda, 3Emiliano Calvo, 4Marloes van Dongen, 5Ferry Eskens, 1Morgan Finlay, 6Fatima Menas, 7Chen Zhu, 8Helene Guillemin-Paveau, 7Giovanni Abbadessa, 9Raymond Perez, 10Aung Naing. 1Hackensack Meridian Health, Hackensack, NJ, USA; 2Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; 3START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain; 4Antoni Van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, North Holland, Netherlands; 5Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; 6Sanofi, Madrid, Madrid, Spain; 7Sanofi, Cambridge, MA, USA; 8Sanofi, Paris, Chilly-Mazarin, France; 9Sanofi, Pennington, NJ, USA; 10The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Background SAR445877 is a fusion protein of high affinity anti-programmed cell death protein 1 (PD1) antibody combined with a detuned interleukin 15 (IL15) (complexed with IL15 receptor sushi domain). SAR445877, via its anti-PD1 moiety, binds to PD-1-expressing T and natural killer (NK) cells and potentially allows for a targeted expansion and activation of CD8+ T and NK cells expressing both PD1 and IL2/15Rbg. Nonclinical studies have demonstrated the potential of SAR445877 as an immune-modulatory agent with good tolerability and therapeutic benefits in various neoplastic disease models including programmed cell death ligand 1 (PD-L1)/PD-L resistant models as a monotherapy. SAR445877 treatments in preclinical models showed increased cytotoxic immune cell recruitment to tumor microenvironment, prolonged survival, and tumor clearance.

Methods This is a first in human, open-label, multicenter, dose escalation and expansion phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activities of SAR445877 administered intravenously as a single agent in adult participants with advanced unresectable or metastatic solid tumors (NCT05584670). The study is conducted in 2 parts. The Part 1 (dose escalation) will determine the maximum tolerated dose or maximum administered dose per occurrence of dose limiting toxicities in the first 28 days (cycle 1 and 2), recommended dose(s), and the overall safety and tolerability profile of SAR445877. A multicohort Part 2 (dose expansion) would assess the safety and preliminary efficacy of SAR445877 (2 dose levels in at least 1 indication, as applicable) and will include cohorts with advanced solid tumors regardless of the tumor proportion score/combined positive score and cohort with a negative expression of the PD-L1. Approximately, 240 participants will be enrolled, of which nearly 75 participants will be enrolled in the Part 1 and 165 participants in the Part 2. Adverse effects will be assessed per National Cancer Institute, Common Terminology Criteria for Adverse Events version 5.0 and American Society for Transplantation and Cellular Therapy consensus grading. Tumor response will be determined according to Response Evaluation Criteria in Solid Tumors criteria. Dose escalation Part 1 is conducted in US, Spain and Netherlands. The study is enrolling participants.

Trial Registration NCT05584670

REFERENCES

http://dx.doi.org/10.1136/jitc-2023-SITC2023.0779